Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - azelastine hydrochloride, quantity: 0.5 mg/ml (equivalent: azelastine, qty 0.457 mg/ml) - eye drops - excipient ingredients: sodium hydroxide; benzalkonium chloride; water for injections; disodium edetate; hypromellose; sorbitol solution (70 per cent) (crystallising) - eyezep is indicated for the treatment and prevention of the symptoms of seasonal and non-seasonal (perennial) allergic conjunctivitis in adults and children 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - olopatadine hydrochloride, quantity: 1.11 mg/ml - eye drops, solution - excipient ingredients: purified water; dibasic sodium phosphate dodecahydrate; hydrochloric acid; sodium chloride; benzalkonium chloride; sodium hydroxide - indicated for the treatment of signs and symptoms of seasonal allergic conjuctivitis. treatment may be maintained for up to 14 weeks, if considered necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; mannitol; sodium hydroxide; purified water; hydrochloric acid; disodium edetate; glacial acetic acid; sodium acetate - treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjunctivitis caused by organisms susceptible to ciprofloxacin in adults and children 12 months of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml); dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; mannitol; sodium hydroxide; water for injections; hyetellose; sodium citrate dihydrate - cosopt is indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma when concominant therapy is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml (equivalent: betaxolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: purified water; disodium edetate; sodium chloride; hydrochloric acid; benzalkonium chloride; sodium hydroxide - indications as at 23 march 1999: betoquin eye drops 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoquin eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: mannitol; sodium citrate dihydrate; benzalkonium chloride; hyetellose; water for injections; sodium hydroxide - trusopt eye drops are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open- angle glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: sodium hydroxide; benzalkonium chloride; sodium acetate; glacial acetic acid; purified water; disodium edetate; hydrochloric acid; mannitol - treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjuctivitis caused by organisms susceptible to ciprofloxacin. indications as at 25 july 1996: treatment of bacterial keratitis (infected corneal ulcers) and severe bacterial conjunctivitis caused by organisms susceptible to ciprofloxacin in adults and children 12 months of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium hydroxide; sodium chloride; hydrochloric acid; disodium edetate; purified water - indications as at 23 march 1999: betoptic 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoptic eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

Australia - English - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - proxymetacaine hydrochloride, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: glycerol; benzalkonium chloride; hydrochloric acid; purified water; sodium hydroxide - indications as at 13 jan 2005 : alcaine eye drops are indicated for procedures in which a rapid and short-acting topical ophthalmic anaesthetic is indicated such as in cataract surgery and suture removal from the cornea, and in tonometry, gonioscopy, removal of corneal foreign bodies, conjunctival scraping for diagnostic purposes, and other short corneal and conjunctival procedures.